FDA approves potential COVID-19 vaccine by Moderna for second-stage study - UPI.com
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moncef Slaoui - Wikipedia
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Current Status of COVID‐19 (Pre)Clinical Vaccine Development - Ye - 2020 - Angewandte Chemie International Edition - Wiley Online Library
PDF) Generating an Anti-HIV Vaccine Using Nucleoside-modified mRNA Encoding Envelope
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Moderna Therapeutics — Wikipédia
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
Nanotechnology for COVID-19: Therapeutics and Vaccine Research. - Abstract - Europe PMC
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
